125 related articles for article (PubMed ID: 21798596)
1. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.
Singh A; Jayanthan A; Farran A; Elwi AN; Kim SW; Farran P; Narendran A
Leuk Res; 2011 Dec; 35(12):1649-57. PubMed ID: 21798596
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
4. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
6. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
7. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Jain HV; Meyer-Hermann M
Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
[TBL] [Abstract][Full Text] [Related]
11. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
15. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
[TBL] [Abstract][Full Text] [Related]
16. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
Yin S; Dong Y; Li J; Fan L; Wang L; Lu J; Vang O; Hu H
Apoptosis; 2012 Apr; 17(4):388-99. PubMed ID: 22179721
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
18. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
19. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
Opydo-Chanek M; Rak A; Cierniak A; Mazur L
Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 modulation to activate apoptosis in prostate cancer.
Bray K; Chen HY; Karp CM; May M; Ganesan S; Karantza-Wadsworth V; DiPaola RS; White E
Mol Cancer Res; 2009 Sep; 7(9):1487-96. PubMed ID: 19737977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
